On June 13, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Augtyro (repotrectinib) for adults and children aged 12 years and older with NTRK-positive solid tumors, including non-small cell lung cancer (NSCLC). The new approval [...]
Contributing Authors: Brittney Nichols, MPH, RN-BSN, Senior Specialist, Science and Research, GO2 for Lung Cancer; Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer; and Renee Botello, MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer Every [...]
On May 16, 2024, the U.S. Food and Drug Administration (FDA) granted Imdelltra (tarlatamab-dlle) accelerated approval for people with extensive stage small cell lung cancer (ES-SCLC) following progression on or after platinum-based chemotherapy. The approval is based on results [...]
Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer The first anti-cancer therapy, mechlorethamine, was approved in 1949. Since then, the U.S. Food and Drug Administration (FDA) has worked to ensure that new lifesaving [...]
Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer On April 18, 2024, the U.S. Food and Drug Administration (FDA) approved Alecensa (alectinib) following surgical resection for people living with early-stage ALK-positive non-small cell lung [...]
Question: My mom was recently diagnosed with lung cancer, and her healthcare team recommended radiation as part of her treatment. We don’t know much about radiation yet. What are the different types of radiation therapy, and how are they [...]
Question: I was recently diagnosed with lung cancer and am on my first line of treatment. I keep hearing that at some point I may develop a resistance to that treatment. What exactly does that mean and how long [...]
Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer You’ve likely started to see artificial intelligence (AI) being used more and more in your everyday life. While the benefits and challenges of using AI [...]
Author: Renee Botello, MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer With decades of research and advances in precision medicine, scientists continue to broaden the treatment standards and options for patients with non-small cell lung cancer (NSCLC). By [...]
Fern Halper, PhD, vice president and senior director of TDWI Research and GO2 board member Fern Halper, PhD has a lifelong passion for data. She has spent more than a decade collecting, managing, and analyzing large amounts [...]